LEGN borrow tightens further as November earnings loom

Legend Biotech enters its November 10 earnings release with short interest still falling but the lending market tightening to its most constrained level in months, a tension that has sharpened since Monday's note.

The short-covering story flagged earlier this week has continued. Short interest now stands at 8.3% of the free float, down 14% on the week from a mid-October peak near 10.8%. That unwind is meaningful: positions were running at roughly 20 million shares in mid-October and have since retreated to around 15.3 million. The covering looks like pre-earnings risk reduction rather than a change of conviction, because the borrow market has moved in the opposite direction simultaneously. Availability tightened further to 33.7% on October 29, recovering slightly from Monday's reading of 29% but still dramatically below the 73% level seen just two weeks ago and the 135% available in late September. To put that in context, when availability runs above 100%, there are more shares available than are currently borrowed. At 33.7%, there is roughly one share available for every three already lent out. The 52-week low is 24.3%, and the current level is closing on it. Cost to borrow has climbed 24% over the past week to 0.79%, a move that tracks the tightening pool, though in absolute terms the rate remains low and does not yet signal squeeze pressure.

The ORTEX short score of 76.3 reflects the overall positioning picture accurately: elevated, but having eased slightly from a peak of 78.9 recorded on October 20. Wikipedia attention spiked sharply in mid-October, with a z-score of 4.15 against the stock's own 90-day history, pointing to a burst of retail interest that coincided with the short covering. Options traders are not adding much signal. The put/call ratio at 0.42 is effectively in line with its 20-day average of 0.42, close to a z-score of zero. That is well below the 52-week high PCR of 1.45, suggesting options positioning is neither defensive nor particularly aggressive relative to recent weeks.

The Street is broadly constructive but has been steadily trimming targets. Barclays maintained its Overweight rating while cutting its price target from $74 to $68 in mid-October. JP Morgan and RBC Capital both lowered targets as well, to $33 and $56 respectively, while keeping their ratings unchanged. The analyst mean target sits at $45.62 against a current price of $21.63, implying the consensus sees substantial upside, though the direction of recent revisions has been consistently downward. The bull case rests on CARVYKTI's clinical durability, a 60.5-month median progression-free survival, 32% year-on-year US sales growth to $472 million in Q2, and rising second-to-fourth-line penetration now near 70% of volume. The bear case centres on competition from bispecifics and anito-cel, execution risk within the J&J partnership, and management's own reduced global sales guidance of $2.66 billion for full-year 2026. EPS momentum is a genuine bright spot, ranking in the 92nd percentile on the 30-day measure, though the eps surprise factor at the 25th percentile suggests the company has not been consistently beating near-term expectations.

On the ownership side, Fidelity (FMR LLC) added 3.2 million shares in the quarter to September 30, lifting its stake to 14.8% of shares. That is a notable incremental buy from one of the largest non-strategic holders. BlackRock added around 650,000 shares over the same period. The dominant shareholder remains Genscript Biotech at 45% of shares, a holding that has been unchanged since February. FMR separately filed a 13G/A in August disclosing a 15% stake, up from 13.1% previously, though as with all 13D/G disclosures the position reflects the level as last reported.

The November 10 print is ten days away. With short interest having unwound from its October peak, borrow availability tightening toward a 52-week low, and analyst targets drifting lower despite broadly positive ratings, the question heading into results is whether CARVYKTI's Q3 commercial trajectory can arrest the slow erosion in Street conviction.